ABO-mismatched platelet and plasma transfusion practices and the potential for transfusion-related alpha-gal syndrome: The Biomedical Excellence for Safer Transfusion Collaborative Study.

Fiche publication

Date publication

juillet 2025

Journal

Transfusion

Auteurs

Membres identifiés du Cancéropôle Est :
Dr ANGELOT-DELETTRE Fanny

Tous les auteurs :
Dunbar NM, Kaufman RM, Bary KS, Bellairs GRM, Cohn CS, Delettre F, Ditcham S, Duarte GC, Ellison A, Fachini R, George CE, Humbrecht C, Louw V, Meier S, Morley S, Mwase M, Robitaille N, Rushford K, Sato T, Schäfer R, Staves J, Takanashi M, Tiberghien P, Wendel S, Wood EM, Ziman A, Murphy MF,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40643108

Résumé

Alpha-gal syndrome (AGS) is caused by IgE antibodies against the alpha-gal oligosaccharide, which is structurally similar to the Group B antigen. Recent case reports of severe allergic transfusion reactions (ATRs) in Group O patients receiving Group B plasma and platelets raise the possibility of a new adverse event, herein called transfusion-related AGS (TRAGS). The primary goal of this study was to assess the frequency of Groups B and AB plasma and platelet transfusions to Group O patients.